

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7718725
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Caitlin Sickler
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	01-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	14:11:52
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P85-FlahertyPhaseIIItrialofBAY.pdf	116666 011a9215c9ac9cc7ae4217ad8aea158830853d75	no	4

### Warnings:

### Information:

2	NPL Documents	P85a- FlahertyAntisensetherapeutics. pdf	709665  514e4bc7b3ff147747fb50594376ee4109881c5d	no	7
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	P86-FOEKENS.pdf	82378  cb493918c557f424c2f40eb6637b3ef5c929f2ba	no	8
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	P87-FORBES.pdf	294817  2d455171d178825a6898224eeefa93f1cd500deb	no	3
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	P88-FRANCO- DissolutionPropertiesandAntic onvulsantActivity.pdf	483946  64005223583c7dfb0ade6e904d6d49631c330	no	11
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	P89- FridmanetalTheMinimalFragme ntsofRaf1andNF1ThatCanSup pressvHaRasInducedMalignant Phenotype.pdf	467153  4c5da5fe7b8499a2fccd770f471e19be238fdec4	no	4
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	P90-Garcia- LopezNewRoutesfortheSynthes isofPyrrolo.pdf	370184  c3a552d6f36f031d0e512d7a5ef3945617f3c8f1	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	P91-GATZEMEIERETAL- PhasellSingleAgent.pdf	228918  98cac275aa6ffc901733658a75114f8bbe9732e9	no	4
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	P92- GeigerAntitumorActivityofaCra fAntisenseOligonucleotideinCo mbination1997.pdf	1058511  e9d3fa6b2a3f35dac776f4c96c38318d1ba8c089	no	7
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	P93- GengetalASpecificAntagonistO fTheP110CatalyticComponent. pdf	358068  1e8256d543881d18840976d9356e5f37f3c978fa	no	7
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	P94a- GeorgeetalNeoplasia v3n5p420.pdf	961363  51ac775ed23c346dc17f24dda853e00dfde a712f	no	8
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	P94- GennaroScienceandpracticePh armacy.pdf	362686  edc77d28d5add5a7eb3a146563bf78e9d93 d5084	no	4
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	P94b-George-et-al-Clin-Cancer- Res-v7-p1932.pdf	942542  fle197b7a8b083fb1adee7e7206effa4d913 a8ce	no	5
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	P95-Abou-Alfaetal.pdf	1220230  a959e7474ccfbb1f3e8c36c3de1e0b5965b2 5d36	no	8
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	P96- GiambartolomeietalSustainedA ctivationofRaf.pdf	471241  dc1f27b1fc9a8b5704a5fbeb70a62101a27 504b	no	5
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	P97- GILLSETALTHEDEVELOPMENTS OFPHOSPHATIDYLINOSITOLETH ERLIPIDANALOGUESASINHIBIT ORSOFTHESERINE.pdf	2605121  c7681a7e6d4580888f90e4c46aeff557d7a 2bb8	no	11
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	P98-GOLLOB- SorafenibScientificRationales. pdf	29880  7cfa83d30561d34558be4b9dbca15ac3f87 625b0	no	1
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	P99- GomezEsquermRNAexpression oftheangiogenesis.pdf	46499  940d83e509c0b52a6ca05d4d6f6c05d6532 51a11	no	2
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	P100- GrantetalSomeHypotensiveThi adiazoles.pdf	272099  5edff436b0ccc7b6727f2208e68fca5888e1 493	no	3
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	P101- GreeneetalProtectiveGroups. pdf	701916  45902e926e4fd89f92b685bb68b8c0d5c3 34aa7	no	4
----	---------------	---	---	----	---

**Warnings:**

**Information:**

**Total Files Size (in bytes):**

11783883

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**